mobileapp
80Bites Mobile App Release
August 14, 2023 09:03 ET | PhysicalMind Institute
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- PhysicalMind Institute, the company that helped bring Pilates to worldwide fame, announces the release of the 80Bites mobile application which helps an...
Obesity Canada logo-en-fr-hor-vert-F2.jpg
Study Finds Benefits of Telephone Cognitive Behavioural Therapy for Bariatric Surgery Patients
August 03, 2023 11:00 ET | Obesity Canada
TORONTO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- New research looking at the mental health and eating behaviours of patients 1-year after bariatric surgery has found that a short, 7-session telephone...
A Call for Help from
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
July 18, 2023 09:29 ET | Spherix Global Insights
Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...
Cardiometabolic Heal
Cardiometabolic Health Congress (CMHC) Launches Focused Digital Education Hubs
July 13, 2023 11:00 ET | Cardiometabolic Health Congress
Boca Raton, FL, July 13, 2023 (GLOBE NEWSWIRE) -- The digital education from worldwide cardiometabolic event leader CMHC has undergone a reorganization. A vast collection of webinars, CME...
Picture3.jpg
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
July 11, 2023 08:30 ET | Clearmind Medicine Inc.
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery...
zealand_logo_RGB_01.png
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
July 03, 2023 06:01 ET | Zealand Pharma
Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396...
Logo.png
Obesity Market to Witness a Robust Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Amgen, Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer, Raziel, Altimmune, Saniona, YSOPIA, Innovent
June 27, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, June 27, 2023 (GLOBE NEWSWIRE) -- Obesity Market to Witness a Robust Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Amgen, Novo Nordisk, Eli Lilly and Company,...
zealand_logo_RGB_01.png
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
June 24, 2023 11:35 ET | Zealand Pharma
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean...
zealand_logo_RGB_01.png
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
June 23, 2023 17:15 ET | Zealand Pharma
Press Release­­­­­­­ No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with...
scilogo.jpg
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023 09:05 ET | SciSparc Ltd
The treatment combines SciSparc's Palmitoylethanolamide (PEA), the active pharmaceutical ingredient of its proprietary CannAmide™, and Clearmind’s MEAI, a novel proprietary psychedelic treatment for...